Oncolytics Biotech Shares Gain on Upcoming Clinical Data Presentations

Oncolytics Biotech to present GOBLET & AWARE-1 trial results for pelareorep at AACR 2026, highlighting immune activation in pancreatic & breast cancer. A new Phase 2 trial in colorectal cancer expands its clinical program.

Oncolytics Biotech Inc. has achieved a significant milestone with the acceptance of two scientific abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting in 2026. This conference is widely recognized within the biotechnology sector as a key barometer for clinical credibility. The company’s lead drug candidate, pelareorep, which is being investigated across multiple tumor types, will be the focal point of these disclosures.

Broadening Clinical Scope with a Third Indication

Further expanding its clinical development program, Oncolytics Biotech initiated a Phase 2 trial in metastatic colorectal cancer in March 2026. This study, designated REO-033, marks a strategic step to widen the potential application of pelareorep into a third major cancer indication, building upon its existing research in pancreatic and breast cancers.

Detailed Findings from Key Trials Set for April 2026

The AACR presentations are scheduled for April 17-22, 2026. They will feature detailed results from two important clinical studies.

Data from the GOBLET trial in metastatic pancreatic cancer—one of the most challenging malignancies to treat—will be shared. The research evaluates a combination therapy consisting of pelareorep, the checkpoint inhibitor atezolizumab, and standard chemotherapy. This regimen was observed to shift tumors into a more immunologically active state. Patients who demonstrated evidence of this immune activation experienced a median progression-free survival of 7.5 months. This compares to 5.6 months for patients without the identified immune response. While early-stage studies naturally involve limited patient numbers, the difference is considered clinically meaningful.

Concurrently, findings from the AWARE-1 study in breast cancer will be presented. These data indicate that treatment with pelareorep stimulates the formation of tertiary lymphoid structures. These biological markers are associated with a targeted mobilization of the body's immune defenses against the tumor. The company is positioning these results to underscore the drug's potential role as a foundational agent for future combination oncology treatments.

Market Anticipation Builds Ahead of Scientific Review

The upcoming conference will serve as a critical forum for the scientific community to assess the presented data. A key focus for investors and industry observers will be gauging whether interest in pelareorep as a combination partner in immuno-oncology continues to grow following these detailed disclosures.